Before closing out their discussion on psoriatic arthritis management, two experts consider how the COVID-19 pandemic has affected their practice.
This article is the first in a series of 4 articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.
Experts conclude their discussion emphasizing the importance of integrative care and how providers can improve outcomes for their patients with fibromyalgia (FM).
Wally Smith, MD, shares his take-home points for patients with sickle cell disease and urges to get tested for sickle cell trait.
Gerald Sacks, MD, and Fariborz Rezai, MD, FCCP FCCM, discuss unmet needs and the future treatment landscape in managing opioid-induced constipation.
A history of bariatric surgery was associated with up to 50% reduced risk of PDAC among a national cohort.
Over 10 years, lifestyle intervention and metformin were cost-effective or cost saving compared with placebo.
If one tunes out the background noise and focuses on two simple concepts--affordability and usability--selecting an EHR becomes a lot less confusing.
Alexy V. Pshezhetsky, Ph.D., professor at the University of Montreal. sits down at WORLDSymposium to stress the importance of researcher involvement throughout the rare disease community.
I'd like to send warm wishes out to everyone at the beginning of this holiday season. Enjoy a warm meal, savor a bit of time at home with loved ones, and trade hugs with children outside of the pediatric office, where they are actually happy to see you.
Ahmed Kandiel, MD, MPH, at the Cleveland Clinic concluded his lecture, "Which Patient/Which Biologic," by reviewing the results of a recently published meta-analysis which examined the risks and benefits of biologic therapy for patients with moderate-to-severe IBD.
These signal voids could help clinicians more specifically identify AMD in patients.
The use of anticoagulation therapy for atrial fibrillation has slowly increased in the last decade, yet many patients at relatively high risk for thromboembolic events are still not receiving anticoagulants. Patients receiving therapy that is intended to maintain sinus rhythm may be at higher risk for underuse of anticoagulation therapy than those receiving rate control therapies. In addition, the increase in the use of anticoagulation therapy appears to have been particularly notable among patients for whom it may not be indicated and in whom safer, less expensive antithrombotic therapies would suffice.
We evaluated the prognostic role of metabolic syndrome after myocardial infarction and found that metabolic syndrome correlated with an increased risk of cardiovascular events and death. The risk of developing diabetes decreased with weight loss in patients with metabolic syndrome. These results indicate that a more aggressive approach to the treatment of patients with metabolic syndrome, particularly with regard to changes in lifestyle, would be beneficial.
We compared the incidence of late clinical events after withdrawal of clopidogrel between subjects treated with drug-eluting stents (DES) and those treated with bare-metal stents. Death and myocardial infarction occurred more frequently among DES-treated subjects during the follow-up period. The results of this study indicate that there may be a penalty for the lower rate of restenosis and reinterventions after DES implantation, in particular, an increased rate of late stent thromboses.
We found sex differences in the pattern of relative strength when riskfactor associations with death from cardiovascular disease (CVD) were evaluated across different periods of follow-up. In women, an increased risk in CVD-related death was associated with diabetes mellitus and smoking; this risk was most prominent in the early follow-up period. Our finding illustrates that clinicians should employ more intense preventive measures in women who are smokers or have diabetes.
R. Presley Swann, MD discussed his preference for CPNBs when treating his patient's post-operative pain.